Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness…. read more.
The increased number of deceased donor liver transplants related to alcoholic hepatitis — up more than 50 percent over predicted numbers — was associated with rising alcohol sales…. read more.
First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
Researchers at Umeå University, Sweden, now demonstrate a method by which specific cell types in human organs can be studied with micrometer precision. The method can be used… read more.
Prosthetic enables a wide range of daily activities, such as zipping a suitcase, shaking hands, and petting a cat. Massachusetts Institute of Technology An MIT-developed inflatable robotic hand… read more.
Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming… read more.
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.
Most able-bodied people take their ability to perform simple daily tasks for granted — when they reach for a warm mug of coffee, they can feel its weight… read more.
Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
